Literature DB >> 25428495

Cancer: Antitumour immunity gets a boost.

Jedd D Wolchok1, Timothy A Chan2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25428495      PMCID: PMC6592276          DOI: 10.1038/515496a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  21 in total

1.  The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus).

Authors:  W B Coley
Journal:  Proc R Soc Med       Date:  1910

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

7.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

8.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.

Authors:  Fei Duan; Jorge Duitama; Sahar Al Seesi; Cory M Ayres; Steven A Corcelli; Arpita P Pawashe; Tatiana Blanchard; David McMahon; John Sidney; Alessandro Sette; Brian M Baker; Ion I Mandoiu; Pramod K Srivastava
Journal:  J Exp Med       Date:  2014-09-22       Impact factor: 14.307

View more
  46 in total

1.  Limitation of tuning the antibody-antigen reaction by changing the value of pH and its consequence for hyperthermia.

Authors:  J Mleczko; A Defort; J J Kozioł; T T Nguyen; A Mirończyk; B Zapotoczny; J Nowak-Jary; E Gronczewska; M Marć; M R Dudek
Journal:  J Biochem       Date:  2015-12-03       Impact factor: 3.387

2.  Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck.

Authors:  Johannes A Veit; Daniela Heine; Julia Thierauf; Jochen Lennerz; Subasch Shetty; Patrick J Schuler; Theresa Whiteside; Dirk Beutner; Moritz Meyer; Inga Grünewald; Gerd Ritter; Sacha Gnjatic; Andrew G Sikora; Thomas K Hoffmann; Simon Laban
Journal:  Head Neck       Date:  2016-02-13       Impact factor: 3.147

Review 3.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

Review 4.  Gut microbiota modulation of chemotherapy efficacy and toxicity.

Authors:  James L Alexander; Ian D Wilson; Julian Teare; Julian R Marchesi; Jeremy K Nicholson; James M Kinross
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-08       Impact factor: 46.802

Review 5.  Radiotherapy and immunotherapy: a beneficial liaison?

Authors:  Ralph R Weichselbaum; Hua Liang; Liufu Deng; Yang-Xin Fu
Journal:  Nat Rev Clin Oncol       Date:  2017-01-17       Impact factor: 66.675

Review 6.  Fever and the thermal regulation of immunity: the immune system feels the heat.

Authors:  Sharon S Evans; Elizabeth A Repasky; Daniel T Fisher
Journal:  Nat Rev Immunol       Date:  2015-05-15       Impact factor: 53.106

Review 7.  Drug repurposing in oncology--patient and health systems opportunities.

Authors:  Francesco Bertolini; Vikas P Sukhatme; Gauthier Bouche
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

8.  Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion.

Authors:  Bertram Bengsch; Andy L Johnson; Makoto Kurachi; Pamela M Odorizzi; Kristen E Pauken; John Attanasio; Erietta Stelekati; Laura M McLane; Michael A Paley; Greg M Delgoffe; E John Wherry
Journal:  Immunity       Date:  2016-08-02       Impact factor: 31.745

9.  Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4.

Authors:  Nathalie Rouas-Freiss; Joel LeMaoult; Jérôme Verine; Diana Tronik-Le Roux; Stéphane Culine; Christophe Hennequin; François Desgrandchamps; Edgardo D Carosella
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

10.  Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Authors:  Andrea Schietinger; Mary Philip; Varintra E Krisnawan; Edison Y Chiu; Jeffrey J Delrow; Ryan S Basom; Peter Lauer; Dirk G Brockstedt; Sue E Knoblaugh; Günter J Hämmerling; Todd D Schell; Natalio Garbi; Philip D Greenberg
Journal:  Immunity       Date:  2016-08-09       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.